New docuseries episode assisted by N.B. right whale researchers
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
5 hours ago
- National Post
Cognito Therapeutics to Present Five Abstracts at AAIC 2025 Highlighting Spectris™ Treatment in Alzheimer's Disease
Article content CAMBRIDGE, Mass. — Cognito Therapeutics, a clinical-stage medical device company pioneering non-invasive neuroprotection therapies against neurodegenerative diseases, today announced that five abstracts featuring its lead investigational device, Spectris™, have been accepted for presentation at the Alzheimer's Association International Conference (AAIC) 2025, taking place July 27–31 in Toronto, Canada. Article content The presentations will showcase clinical, neurophysiological, and biomarker data supporting Spectris™, an at-home device designed to deliver personalized, sensory-driven gamma stimulation to slow the progression of Alzheimer's disease. Article content Among the highlights is an oral presentation selected by the International Society to Advance Alzheimer's Research and Treatment (ISTAART): Article content Preservation of Neurophysiological Signals and White Matter with 40Hz Sensory Stimulation in Alzheimer's Disease Session: ISTAART Oral Session Presenter: Chandran Seshagiri, PhD Date/Time: Saturday, July 26, 2025, 10:15–11:15 AM Article content In addition, Cognito will present five poster sessions: Article content 'These presentations underscore the broad neuroprotective potential of Spectris, from preserving white matter and functional connectivity to measuring real-world benefits that matter to patients,' said Ralph Kern, MD, MHSc, Chief Medical Officer of Cognito Therapeutics. 'We look forward to sharing these latest insights with the global neuroscience community at AAIC.' Article content Spectris™ is currently being evaluated in the ongoing HOPE pivotal clinical trial (NCT05637801) for Alzheimer's disease. It is an investigational device and has not yet received regulatory approval for commercial use from the U.S. Food and Drug Administration or any other health authority. Article content About Cognito Therapeutics Article content Cognito Therapeutics is a late clinical-stage medical device company pioneering neuroprotective therapies to address the unmet needs of patients living with CNS disorders. Its lead product, Spectris™ AD, is an at-home therapeutic device that uses non-invasive, sensory-driven neurostimulation to evoke gamma frequency brain activity. The company's feasibility studies have shown the potential for Spectris AD to preserve cognition, daily function, and slow brain atrophy in patients diagnosed with mild-to-moderate AD. Cognito is headquartered in Cambridge, MA. For more information, visit and follow @cognitotx. Article content Article content Article content Article content Contacts Article content Media Contact Article content Article content Kimberly Ha Article content Article content Article content
CBC
5 hours ago
- CBC
Canada needs agency to manage public UFO sightings, says new federal report
Canada needs a transparent, public-facing agency in charge of managing reports of mystifying things seen darting, blinking or hovering through our skies, according to a new report commissioned by Canada's top scientist. The Sky Canada Project report published this week calls for a federal framework for managing UFO sightings by the public and pilots as a replacement for the current patchwork of protocols across departments that "hinder[s] scientific investigation." "There is some evidence that there's something really unusual going on in the skies … we just don't have enough information," said Winnipeg-based science writer Chris Rutkowski, director of the long-running Canadian UFO Survey who was consulted for the report. The Sky Canada Project was created in 2022 by the Office of the Chief Science Advisor, Mona Nemer, partly in response to growing public interest in the topic of UFOs — also known as UAP, or unidentified anomalous or aerial phenomena. Staff set out to identify challenges related to data collection on UAP sightings and provide a summary of how other countries approach the issue. The project was tasked with doing an environmental scan of historical reporting practices across the federal government and present-day UAP procedures of different federal agencies, and to consult non-governmental groups and experts in the country tracking and receiving UAP reports from the public. The report found Canada's "fragmented" UAP reporting protocols across departments "complicates the application of scientific principles ... making it onerous, if not impossible, for researchers to access and compile data for rigorous, science-based analysis." "Canada would benefit from an improved process for reporting, collecting, and studying UAP sightings," reads a section of the report. Canada once had a centralized office for that run by the National Research Council beginning in 1967, with help from the RCMP. That's the same year one of Canada's best-documented UFO cases emerged in Falcon Lake, Man. The NRC effort ended in 1995. Roles and responsibilities were scattered among the Canadian Space Agency, Transport Canada, NavCanada — and Rutkowski, who amassed vast civilian, military, police and air traffic controller records of UAP reports dating back to the 1940s that Sky Canada has used in its analysis. No definitive proof of E.T. In recent years, NASA has conducted an independent UAP study; the U.S. Office of the Secretary of Defence erected the All-Domain Anomaly Resolution Office (AARO) to investigate UAP reports by military personnel; and Congress has held multiple public hearings centering on national security concerns posed by UAP and alleged government coverups. Most UAP sightings happen to be planes, atmospheric conditions, planets or stars or meteors, satellites, weather balloons, drones, experimental craft, optical illusions or other mundane phenomena. To date, there's still no evidence definitively proving extraterrestrial life is here or exists, notes the Sky Canada report. "Nonetheless, some UAP sightings — for which data exist — remain unexplained even after investigation," the report says. That uncertainty adds to the cultural fascination around UAPs. "There is some interesting stuff being reported," said Rutkowski. "It doesn't necessarily prove that aliens are visiting us. It proves that some unusual cases are baffling." Dispelling disinformation The report also identifies the need to increase transparency and build public trust through proactive disclosure of UAP case details in an effort to combat mis- and dis-information, and "pre-bunk" conspiracy theories before they spread. "Everyone loves the idea of searching for UFOs or UAPs," said Sara Seager, a Canadian-American astrophysicist at MIT focused on the search for Earth-like planets. "Taking that into a way to educate people about misinformation, about challenging your own assumptions ... I had never thought of the field in those terms before, and that was a really, really exciting new thing to me." The report suggests the Canadian Space Agency might be a good fit to lead public UAP data management. Seager thinks a post-secondary institution might be more appropriate. "Universities are used to educating people, so perhaps there's a way they can, as the report said, parse this into some kind of outreach about planets and stars and natural phenomena," said Seager, who wasn't involved in the report. Report cites Harvard UAP team Sky Canada never set out to prove whether we're alone in the universe, the report says, nor was that project in particular to analyze data of sightings. Astrophysicist Avi Loeb is hunting for evidence of alien technology within Earth's atmosphere and our solar system through a data-driven approach. Loeb wasn't involved in the report either. However, his work as head of Harvard's Galileo Project was cited by Sky Canada Project as an initiative that could prove "crucial in transitioning from anecdotal evidence to more scientifically rigorous analysis" of UAP. That project will have three uniquely-constructed observatories in different U.S. states upon completion that use sensors and machine learning to spot and measure speed, size, relative distance and other variables of UAP flitting around American airspace — including balloons or craft from rival governments engaging in espionage. "The software we develop, the sensors we put together can be used by the Department of Defence if these are human-made objects, so I wouldn't feel like I wasted my time if we end up finding only human made objects," said Loeb. "This subject of course touches upon national security for Canada and the U.S. and I think co-operation would be very much appreciated." Rutkowski appreciates Sky Canada's calls to encourage pilots to report sightings and for more science on a topic still at times dogged by stigma and a "ridicule factor." "Things are looking up and you know, there's no question that the truth is out there," he said. "Unfortunately, we're stuck down here."
National Post
6 hours ago
- National Post
Elucid Names Richard E. Kuntz, MD, MSc and Shamiram Feinglass, MD, MPH Board Directors
Article content BOSTON & SCCT ANNUAL MEETING, MONTREAL — Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, has made two additions to its Board of Directors. The company named Richard E. Kuntz, MD, MSc and Shamiram Feinglass, MD, MPH as board directors. Article content These appointments will help guide Elucid as it accelerates its clinical research strategy, commercializes its flagship PlaqueIQ TM coronary plaque assessment technology, and continues development of its investigational FFR prediction model, based on PlaqueIQ. PlaqueIQ is the first and only FDA-cleared, non-invasive plaque analysis based on objective histology rather than subjective CCTA visual estimates. PlaqueIQ quantifies and classifies plaque morphology based on ground-truth histology, the gold standard for characterization of plaques. The software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk. Article content An experienced medical technology executive and clinical expert, Dr. Kuntz is former senior vice president and chief medical and scientific officer of Medtronic plc. Prior to joining Medtronic, he was the founder and chief scientific officer of the Harvard Clinical Research Institute (HCRI), a university-based contract research organization that coordinates National Institutes of Health (NIH) and industry clinical trials with the U.S. Food and Drug Administration (FDA). Dr. Kuntz has directed several multicenter clinical trials and has authored more than 250 original publications. Dr. Kuntz was an associate professor of Medicine at Harvard Medical School, chief of the division of Clinical Biometrics, and an interventional cardiologist in the division of cardiovascular diseases at the Brigham and Women's Hospital in Boston. Article content Dr. Feinglass is a managing director at Manatt Health working across the business, medical, and policy needs of health systems, life sciences, medical device, digital health and diagnostic companies globally. A global leader in health care, Dr. Feinglass has served as an executive and chief medical officer in large multi-national life sciences corporations including Danaher and Zimmer-Biomet. In parallel, she has driven policy changes alongside senior government officials around the world to influence health policy, regulation, and access. A former regulator at U.S. Centers for Medicare and Medicaid Services (CMS) and commander in the U.S. Public Health Service with extensive regulatory and legislative experience, Dr. Feinglass is on faculty at the John's Hopkins Bloomberg School of Public Health, Department of Mental Health and is a member of the Board of Directors of Sandoz AG. Article content 'We are honored that Dr. Richard E. Kuntz and Dr. Shamiram Feinglass have joined Elucid's Board of Directors,' said Elucid CEO Kelly Huang, PhD. 'Rick lends an important and experienced interventional cardiology view, as well as expertise in clinical trial strategy and execution, and product innovation strategy. Coupled with Shami's unparalleled expertise in market access, policy making, and regulatory strategy, the two will be invaluable as we push forward our vision of a future where cardiac care is personalized, precision patient care versus risk factor and population-based care.' Article content About Elucid Article content Elucid is a Boston-based AI medical technology company dedicated to developing technology designed to provide physicians with a more precise view of atherosclerosis (coronary plaque buildup), the root cause of cardiovascular disease. The company's PlaqueIQ TM image analysis software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk of disease. PlaqueIQ includes the only FDA-cleared computed tomography angiography (CTA) algorithm that objectively quantifies plaque morphology validated against ground truth histology, the gold standard for characterization of plaque, as indicated by renowned pathologists. PlaqueIQ equips physicians with critical information regarding the type and amount of plaque in arteries that can lead to heart attack and stroke. Elucid is also pursuing an indication for FFR CT, derived from its plaque algorithm, to help identify coronary blockages and the extent of ischemia non-invasively. For more information, visit Article content Article content Article content Article content Contacts Article content Media Contact: Article content Article content Sam Choinski Article content Article content Article content Article content
